Fred D. Lublin, MD is the Saunders Family Professor of Neurology and the Director of the Corinne Goldsmith Dickinson Center for Multiple Sclerosis at the Mount Sinai Hospital. He is an internationally renowned authority on the scientific and clinical aspects of Multiple Sclerosis (MS); he is also one of the foremost authorities regarding experimental therapies.  

 

Dr. Lublin received his medical degree at Jefferson Medical College, Philadelphia, PA.  He completed his internship in Internal Medicine at the Bronx Municipal Hospital, Albert Einstein Medical Center, and his residency at the New York Hospital, Cornell Medical Center. He is certified in neurology.  

 

Dr. Lublin is a neuroimmunologist and as such has a special interest in immune functions and abnormalities that affect the nervous system. He has been involved in both and clinical and basic science research. He and his colleagues were among the first in the country involved with studies of Interferon beta-1b, which was approved by the Food & Drug Administration in 1993 to treat the relapsing-remitting form of Multiple Sclerosis.  

 

He is currently involved with several new clinical research protocols on promising agents for treating various aspects of MS and is the national Coordinating Investigator for a multi-center trial of combination therapy in MS.  

 

Dr. Lublin was chairman of the National Multiple Sclerosis Society (USA) advisory committee on clinical trials of new MS drugs and he was chair of the Clinical Advisory Committee of the New York City Chapter of the National MS Society and a past National Board member of the Society.  Dr. Lublin and his colleagues at the National MS Society (USA) have re-defined the clinical course definitions of MS using data from a survey of the international MS community. He has chaired a task force on the ethics of placebo-controlled trials in MS. Dr. Lublin was a member of the panel that has re-defined the diagnostic criteria for MS.  

 

Dr. Lublin has served as a consultant to the National Institutes of Health and to many pharmaceutical/biotech companies in all phases of new drug development and in preparation for presentation to the FDA and their advisory panels. He was the Principal Investigator of the NIH-sponsored multicenter Combination Therapy study in Multiple Sclerosis.  

 

Dr. Lublin is a member of many professional societies and advisory boards. He has published numerous scientific articles and has served as a consultant to the NIH, as well as to pharmaceutical and biotech companies in all phases of drug development, and in preparation for drug presentation to the FDA and its advisory panels.